EcoDrugPlus

Proteasome Subunit Alpha Type-6-Like

Ensembl ID : ENSAOCG00000018194
Gene Symbol: LOC111581703
3 Cross references
229 Possible Orthologues:

Proteasome Subunit Alpha Type-7

Ensembl ID : ENSAOCG00000023884
Gene Symbol: LOC111580250
3 Cross references
183 Possible Orthologues:

Proteasome Subunit Beta 11

Ensembl ID : ENSAOCG00000009528
Gene Symbol: PSMB11
3 Cross references
170 Possible Orthologues:

Proteasome Subunit Beta Type-2

Ensembl ID : ENSAOCG00000015490
Gene Symbol: LOC111564107
3 Cross references
218 Possible Orthologues:

Proteasome Subunit Beta Type-2-Like

Ensembl ID : ENSAOCG00000011121
Gene Symbol: LOC111571274
3 Cross references
204 Possible Orthologues:

Proteasome Subunit Beta Type-5-Like

Ensembl ID : ENSAOCG00000009594
Gene Symbol: LOC111584962
3 Cross references
223 Possible Orthologues:

Proteasome Subunit Beta Type-7-Like

Ensembl ID : ENSAOCG00000022707
Gene Symbol: LOC111579144
3 Cross references
172 Possible Orthologues:

Proteasome Subunit Beta Type-7-Like

Ensembl ID : ENSAOCG00000022660
Gene Symbol: LOC111579146
3 Cross references
215 Possible Orthologues:

Proteasome Subunit Beta Type-9

Ensembl ID : ENSAOCG00000000185
Gene Symbol: LOC111584584
3 Cross references
209 Possible Orthologues:

Protein Arginine Methyltransferase 5

Ensembl ID : ENSAOCG00000009327
Gene Symbol: PRMT5
3 Cross references
199 Possible Orthologues:

Protein Farnesyltransferase Subunit Beta-Like

Ensembl ID : ENSAOCG00000005771
Gene Symbol: LOC111569570
3 Cross references
203 Possible Orthologues:

Protein Farnesyltransferase/geranylgeranyltransferase Type-1 Subunit Alpha-Like

Ensembl ID : ENSAOCG00000000984
Gene Symbol: LOC111567609
4 Cross references
221 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).